Jazz Pharmaceuticals (JAZZ) — insider trading
Health Care · NASDAQ
Jazz Pharmaceuticals (JAZZ) has 78 reported SEC Form 4 insider transactions in our data, including 21 open-market sales among the most recent 78 (latest 2026-10-06).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | GALA RENEE D | Director, Officer (President & CEO) | Open-market sale | 2,000 | $236.40 | $472.8K | Form 4 |
| 2026-10-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $230.33 | $1.38M | Form 4 |
| 2026-09-10 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Open-market sale | 1,200 | $240.94 | $289.1K | Form 4 |
| 2026-09-08 | Henderson Mary Elizabeth | Officer (SVP, Technical Operations) | Shares withheld for taxes / exercise cost | 15 | $241.20 | $3.6K | Form 4 |
| 2026-09-08 | Henderson Mary Elizabeth | Officer (SVP, Technical Operations) | Shares withheld for taxes / exercise cost | 1,412 | $243.03 | $343.2K | Form 4 |
| 2026-09-08 | GALA RENEE D | Officer (President & CEO) | Open-market sale | 2,000 | $243.03 | $486.1K | Form 4 |
| 2026-09-08 | GALA RENEE D | Officer (President & CEO) | Shares withheld for taxes / exercise cost | 1,967 | $246.81 | $485.5K | Form 4 |
| 2026-09-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $250.13 | $1.50M | Form 4 |
| 2026-08-31 | Kennedy Patrick | Director | Shares withheld for taxes / exercise cost | 1,840 | $241.39 | $444.2K | Form 4 |
| 2026-08-31 | Kennedy Patrick | Director | Shares withheld for taxes / exercise cost | 15 | $244.06 | $3.7K | Form 4 |
| 2026-08-31 | Smith Mark Douglas | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | Smith Mark Douglas | Director | Shares withheld for taxes / exercise cost | 14 | $244.64 | $3.4K | Form 4 |
| 2026-08-31 | McSharry Heather Ann | Director | Shares withheld for taxes / exercise cost | 1,840 | $241.39 | $444.2K | Form 4 |
| 2026-08-31 | McSharry Heather Ann | Director | Shares withheld for taxes / exercise cost | 15 | $244.64 | $3.7K | Form 4 |
| 2026-08-31 | Winningham Rick E | Director | Shares withheld for taxes / exercise cost | 14 | $244.64 | $3.4K | Form 4 |
| 2026-08-31 | Winningham Rick E | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | LOVE TED W | Director | Shares withheld for taxes / exercise cost | 737 | $241.39 | $177.9K | Form 4 |
| 2026-08-31 | LOVE TED W | Director | Shares withheld for taxes / exercise cost | 6 | $244.06 | $1.5K | Form 4 |
| 2026-08-31 | RIEDEL NORBERT G | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | RIEDEL NORBERT G | Director | Shares withheld for taxes / exercise cost | 14 | $244.64 | $3.4K | Form 4 |
| 2026-08-31 | Henderson Mary Elizabeth | Officer (SVP, Technical Operations) | Shares withheld for taxes / exercise cost | 16 | $244.64 | $3.9K | Form 4 |
| 2026-08-31 | Henderson Mary Elizabeth | Officer (SVP, Technical Operations) | Shares withheld for taxes / exercise cost | 2,076 | $241.39 | $501.1K | Form 4 |
| 2026-08-31 | Hamill Laura | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | Hamill Laura | Director | Shares withheld for taxes / exercise cost | 14 | $244.06 | $3.4K | Form 4 |
| 2026-08-31 | ENRIGHT PATRICK G | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | ENRIGHT PATRICK G | Director | Shares withheld for taxes / exercise cost | 14 | $244.64 | $3.4K | Form 4 |
| 2026-08-31 | Cook Jennifer E. | Director | Shares withheld for taxes / exercise cost | 1,692 | $241.39 | $408.4K | Form 4 |
| 2026-08-31 | Cook Jennifer E. | Director | Shares withheld for taxes / exercise cost | 14 | $244.06 | $3.4K | Form 4 |
| 2026-08-31 | COZADD BRUCE C | Director | Shares withheld for taxes / exercise cost | 1,209 | $241.39 | $291.8K | Form 4 |
| 2026-08-31 | COZADD BRUCE C | Director | Shares withheld for taxes / exercise cost | 10 | $244.06 | $2.4K | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion (derivative) | 27,584 | — | $0 | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion (derivative) | 26,116 | — | $0 | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion (derivative) | 2,916 | — | $0 | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion (derivative) | 884 | — | $0 | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 300 | $252.76 | $75.8K | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 9,259 | $251.95 | $2.33M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 19,639 | $250.60 | $4.92M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 18,113 | $250.02 | $4.53M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 11,423 | $248.67 | $2.84M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Open-market sale | 18,187 | $247.86 | $4.51M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion | 2,916 | $137.12 | $399.8K | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion | 27,584 | $137.12 | $3.78M | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion | 884 | $113.10 | $100.0K | Form 4 |
| 2026-08-27 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Option exercise / conversion | 26,116 | $113.10 | $2.95M | Form 4 |
| 2026-08-05 | COZADD BRUCE C | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | RIEDEL NORBERT G | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | ENRIGHT PATRICK G | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | McSharry Heather Ann | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Mulligan Seamus | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Cook Jennifer E. | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Smith Mark Douglas | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Kennedy Patrick | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Hamill Laura | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | LOVE TED W | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Winningham Rick E | Director | Grant / award / vesting | 1,605 | — | $0 | Form 4 |
| 2026-08-05 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 780 | $261.62 | $204.1K | Form 4 |
| 2026-08-03 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $252.98 | $1.52M | Form 4 |
| 2026-07-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $240.47 | $1.44M | Form 4 |
| 2026-06-30 | Johnson Philip L | Officer (EVP & Chief Financial Officer) | Shares withheld for taxes / exercise cost | 3,343 | $237.72 | $794.7K | Form 4 |
| 2026-06-30 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Shares withheld for taxes / exercise cost | 2,678 | $237.72 | $636.6K | Form 4 |
| 2026-06-30 | Iannone Robert | Officer (EVP, Global Head of R&D & CMO) | Shares withheld for taxes / exercise cost | 3,764 | $237.72 | $894.8K | Form 4 |
| 2026-06-30 | GALA RENEE D | Officer (President & CEO) | Shares withheld for taxes / exercise cost | 4,835 | $237.72 | $1.15M | Form 4 |
| 2026-06-30 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Shares withheld for taxes / exercise cost | 2,527 | $237.72 | $600.7K | Form 4 |
| 2026-06-15 | Smith Mark Douglas | Director | Open-market sale | 1,157 | $230.55 | $266.7K | Form 4 |
| 2026-06-10 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Open-market sale | 1,200 | $231.83 | $278.2K | Form 4 |
| 2026-06-03 | GALA RENEE D | Officer (President & CEO) | Bona fide gift | 600 | — | $0 | Form 4 |
| 2026-06-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $235.12 | $1.41M | Form 4 |
| 2026-05-28 | Mulligan Seamus | Director | Option exercise / conversion (derivative) | 3,415 | — | $0 | Form 4 |
| 2026-05-28 | Mulligan Seamus | Director | Option exercise / conversion | 3,415 | $138.08 | $471.5K | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion (derivative) | 6,907 | — | $0 | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Open-market sale | 6,907 | $235.41 | $1.63M | Form 4 |
| 2026-05-28 | Pearce Samantha | Officer (EVP, Chief Commercial Officer) | Option exercise / conversion | 6,907 | $109.45 | $756.0K | Form 4 |
| 2026-05-28 | Patil Neena M | Officer (EVP & Chief Legal Officer) | Open-market sale | 1,192 | $236.97 | $282.5K | Form 4 |
| 2026-05-22 | McSharry Heather Ann | Director | Open-market sale | 2,000 | $241.00 | $482.0K | Form 4 |
| 2026-05-22 | Winningham Rick E | Director | Option exercise / conversion (derivative) | 3,415 | — | $0 | Form 4 |
| 2026-05-22 | Winningham Rick E | Director | Open-market sale | 2,741 | $241.57 | $662.1K | Form 4 |
| 2026-05-22 | Winningham Rick E | Director | Option exercise / conversion | 3,415 | $138.08 | $471.5K | Form 4 |
| 2026-05-01 | COZADD BRUCE C | Director | Open-market sale | 6,000 | $203.33 | $1.22M | Form 4 |
Ask the chat about JAZZ's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Jazz Pharmaceuticals (JAZZ).
Last updated 2026-10-06 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.